In a previous report the disappearance curve of plasma radioactivity after intravenous injection of I131-labeled 1-thyroxine was employed to determine the rate of hormone degradation or removal in subjects with thyroid disease (1) . Thyroxine degradation was slower than normal in untreated myxedema, and faster than normal in thyrotoxicosis. These findings were in agreement with those of Berson and Yalow (2) and Ingbar and Freinkel (3) .
The present work was undertaken to observe the effects of treatment and attainment of the euthyroid state, with studies on individual subjects before and after therapy.
MATERIAL AND METHODS
I"31-labeled 1-thyroxine was obtained in 1 mc. shipments from Abbott Laboratories, Oak Ridge, Tenn. The radiothyroxine was diluted in 50 to 75 ml. sterile saline to which approximately 50 mg. Red Cross albumin had been added to prevent adsorption by vessel walls. The injections were carried out within one to two hours of the preparation of dilute solutions. The subjects received tracer amounts (approximately 50 /Ac. in 2 to 10 ug. thyroxine) by intravenous injection. Heparinized venous blood samples were taken 10 minutes after injection and daily or on alternate days for two weeks or longer. The plasma radioactivity was assayed in a well-type scintillation counter which recorded approximately one million counts per minute (cpm) per microcurie of I' (42 per cent overall efficiency) above a background of 130 cpm. Corrections for radioactive decay were made when necessary. Usually all plasma samples from a given patient and diluted aliquots of the administered compound were counted together after conclusion of the study, obviating the need for decay correction.
In all subjects two or more plasma protein bound iodine (PBI) or butanol extractable iodine (BEI) determinations were carried out1 (4, 5) . The BEI was done to avoid interference from previously administered inorganic iodine. The two determinations were used interchangeably in the calculations of "organic iodine" figures; PBI ordinarily exceeds BEI by approximately 0.6 jgg. per cent in the absence of inorganic iodine (5).
Two or more basal metabolic rate (BMR) determinations were performed on separate days, usually during the period of study.
Iodine prefeeding was employed to prevent reutiliza- tion of the I`1-label in the thyrotoxic subjects only. Both treated and untreated thyrotoxic subjects received Lugol's solution, 15 drops daily, prior to and throughout studies. The myxedematous and normal control subjects did not receive iodine prefeeding since previous studies (1, 3) indicated that the error would be negligible except in hyperthyroid subjects.
Calculations. The injection of radiothyroxine was followed by a relatively rapid fall in the radioactivity of the plasma (Figures 1 through 4) . This was attributed to the diffusion of the tracer out of the plasma throughout the body's extrathyroidal organic iodine (EOI) pool. After two days the plasma radioactivity declined more gradually, forming a straight line when plotted semilogarithmically (Figures 1 through 4 Myxedema. Eight cases of myxedema were studied after various periods of replacement therapy with desiccated thyroid which, except in specified instances, had restored euthyroid status, as judged by clinical appearance, PBI and BMR determinations. All but one case had studies before therapy, five having been reported previously (1) . Two of the eight cases (Nos. 2 and 7) had myxedema following resection of nontoxic goiter. The rest had spontaneous idiopathic myxedema.
RESULTS
The findings are listed in Table I , and illustrated in Figures 1 through 5. Definite changes were observed following treatment, and were especially pronounced in the thyrotoxic subjects. In subjects studied both before and after treatment, the changes in turnover rates are depicted in Figure 5 , which shows changes in the same direction in all instances except one in each group. (Figure 2 ), showed no appreciable change in disappearance curve after I'3l treatment and attainment of the euthyroid state. The disappearance rate was slightly accelerated in the initial and final studies. The patient had been maintained nearly euthyroid with antithyroid medications begun three weeks before and continued during the initial study (Tapazole®, 40 mg. daily; later propylthiouracil, 400 mg. daily). Although the disappearance curve remained the same, the pool size and degradation rate fell markedly after I'3l treatment (Table I and Figure 2 ) in a study carried out during the administration of Lugol's solution.
In Subject L.S., No. 13, illustrated in Figure 1 , despite the marked slowing of disappearance rate there was still some elevation of the pool size and degradation rate (Table I ). . 19) , the remaining 17 subjects all showed reductions in turnover rate, pool size and degradation rate either to the normal range or below it. Figure 3 was selected to illustrate an instance of a very slow turnover following treatment. Subject R.D., No. 11, was clinically hypothyroid, and the PBI, turnover kinetics, pool size and degradation rate were all within the range seen in spontaneously occurring myxedema (Table I) The time interval after treatment varied. Subject L.D., No. 10, was restudied only one month after subtotal thyroidectomy and revealed marked alterations, illustrating the rapidity with which such changes could occur.
Myxedema
In contrast, the changes were slower to appear in the myxedematous patients on replacement therapy. In general the curves and values were found to have reached or approached the normal range only after considerable periods on replacement therapy. Thus, Subject H.L., No. 1 ( Figure 4 and 
DISCUSSION
In the previous study (1) the metabolism of I'8"-labeled 1-thyroxine was strikingly different from normal in the hyper-and hypothyroid states. These differences were evident in the turnover rates as per cent per day, the pools of extrathyroidal hormone, and the degradation rates which represented products of pools and turnovers. All parameters were higher than normal in thyrotoxicosis, and lower in myxedema.
The present study showed quite marked changes after treatment, especially in the thyrotoxic subjects. Reversion to the normal range was seen as early as one month after subtotal thyroidectomy. Nineteen of the 20 thyrotoxic subjects had posttherapy values approximating the normal range or below it, in three instances duplicating the findings seen in spontaneous myxedema.
The exceptional patient M.O., No. 12 ( Figure  2) , showed a slightly accelerated turnover rate both in an initial study while maintained nearly euthyroid on drugs, and in the final study. Although the disappearance curves were essentially the same, the pool size and degradation rate became much smaller. Determination of thyroxinebinding protein (TBP) through the courtesy of Dr. Jacob Robbins revealed no abnormality in this patient's serum. With the exception of this one instance, the present findings of marked changes after therapy of thyrotoxicosis did not agree with the preliminary report of Ingbar and Freinkel (6) who observed accelerated turnovers in most patients after therapy.
Although myxedematous subjects on replacement therapy did reveal changes to or toward the normal range, these changes occurred more slowly than with treatment of thyrotoxicosis. The previous report (1) demonstrated that rapid massive replacement therapy with triiodothyronine and thyroxine failed to alter disappearance curves in studies continued 7 to 10 days after treatment. Thus, there was no change in fractional turnover rate despite increased absolute amount of hormone removed with elevation of PBI concentration. Subsequent similar studies (7) continued as long as one month showed no change in plasma disappearance curves, nor in urinary excretion of the radioactive label. Moreover, these findings have been confirmed and extended by Richards, Freinkel and Ingbar (8) . It is therefore quite evident that the turnover curves of myxedematous subjects are changed only by relatively prolonged replacement therapy.
In the previous report (1) (13) have not suggested that binding capacity differs from normal in the hypo-or hyperthyroid state. On the other hand, Robbins and Rall, using reverse-flow electrophoresis, found the absolute TBP concentration slightly higher than normal in myxedema, but not different from normal in hyperthyroidism (14) .
In any event, where plasma thyroxine concentration is higher, one might expect that the extent of "saturation" of TBP would be greater. The thyroxine not bound to TBP is "non-specifically" bound to albumin. The existence of a minute amount of "unbound" or "free" thyroxine has been postulated by Robbins and Rall based upon computations of protein association constants. Moreover, these authors have suggested that the amount of "free" thyroxine in the plasma may determine the thyroxine degradation rate, and have presented calculations compatible with such a hypothesis. On the other hand, the failure of very large doses of intravenous thyroxine to alter the turnover rate, as noted above (1), would appear to argue against such a conception. The attainment of PBI values as high as 26 micrograms per cent (1) would be expected to provide much "free" thyroxine despite possible increased thyroxine binding capacity of myxedematous plasma (14) .
The data and inferences of the author, cited above, receive support from the work by Ingbar's group (8) which includes observations of displacement of thyroxine from TBP onto albumin after thyroxine loading. Despite abrupt increase of the thyroxine pool after loading, the fractional rate of turnover was unaffected. In contrast, subjects made hypermetabolic by prolonged administration of triiodothyronine showed accelerated thyroxine turnover despite reduction in PBI and computed "free" thyroxine values.
Such observations suggest that factors other than TBP must be implicated in thyroxine turnover. Recent work has underscored the need for further clarification of the nature of the binding protein or proteins. Employing starch gel electrophoresis, Rich and Bearn (15) have reported that the first prealbumin band contained 60 per cent of the radioactivity of added radiothyroxine, and had a binding capacity far in excess of that previously reported for the interalpha zone. Ingbar (16) used a different electrophoretic method to reveal thyroxine bound in both interalpha and prealbumin areas, the latter possessing greater binding capacity, which, however, was diminished in untreated Graves' disease.
Future work will be required to settle definitely whether plasma protein binding or some ratelimiting step related to peripheral tissue metabolism is of paramount importance in determining thyroxine turnover.
A further hypothesis, embracing both of these alternatives, would assign a significant role to the turnover rate of the thyroxine binding protein itself. This would be consistent with previous evidence on serum protein metabolism, such as I131-tagged albumin turnover studies which have demonstrated the accelerating effect of thyroid hormone (7, 17, 18) .
SUM MARY
1. The disappearance curve of plasma radioactivity after intravenous injection of I131-labeled 1-thyroxine was employed to determine the rate of hormone degradation or removal.
2. Thyroxine degradation was slower than normal in untreated myxedema, and faster than normal in thyrotoxicosis.
3. In 19 of 20 cases of thyrotoxicosis treated with radioiodine or surgery, the degradation rate became approximately normal or even below normal. Pronounced changes were observed as rapidly as one month after subtotal thyroidectomy. In a single instance, the disappearance curve remained slightly accelerated after attainment of euthyroidism.
4. In two cases of postradioiodine hypothyroidism and one post thyroidectomy patient, the rate was as slow as that seen in spontaneously occurring myxedema.
5. In myxedematous patients on replacement therapy, the disappearance curve might remain unaltered for as long as one to four months despite attainment of euthyroid status. After prolonged replacement therapy of myxedema for six months or more, the degradation rates became normal or changed in the direction of normal.
6. The results suggested that the rate of removal of circulating thyroxine is a significant parameter of hormone metabolism possibly reflecting a function of peripheral tissue metabolism and/or extent of association with thyroxine-binding protein.
